Company Overview
Jupiter Neurosciences, Inc. operates as a clinical stage research and development pharmaceutical company dedicated to developing resveratrol platform products specifically for the treatment of neuroinflammation. The company is situated within the healthcare sector, functioning as a biotechnology entity that focuses on advancing therapeutic solutions for rare inherited diseases such as Friedreich's Ataxia. The organization maintains a very small operational scale, employing only four individuals while managing a market capitalization of $12.05 million. This valuation indicates that the company is a micro-cap biotechnology firm operating with limited financial resources, a position typical for early-stage research entities that have not yet achieved commercial revenue but possess significant intellectual property potential in the neurology space.
Financial Health
The company reports no annual revenue figures available for the trailing twelve months, and consequently, the net income for the period stands at -$7,597,493, while EBITDA is not applicable due to the lack of operating cash earnings. The substantial negative net income relative to zero revenue highlights a cost structure dominated by high research and development expenditures, clinical trial costs, and general administrative expenses that exceed any potential income streams. Free cash flow is reported at -$3,161,967, which signifies a heavy burn rate and indicates that the company is consuming its cash reserves to fund its product pipeline rather than generating positive operating liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the fact that the company has not yet generated profitable sales to establish a historical margin profile. On the balance sheet, the company holds cash of $723,797 against total debt of $180,393, resulting in a debt-to-equity ratio of 314.18, which suggests a highly leveraged financial position relative to its equity base despite the absolute dollar amount of debt being low. The current ratio stands at 0.65, indicating that current assets are insufficient to cover current liabilities without relying on external financing or asset liquidation. Furthermore, the return on equity is not applicable, and the return on assets is reported at -354.9%, revealing that management is currently utilizing the company's asset base to generate significant losses rather than returns.
Valuation Assessment
The trailing twelve-month P/E ratio is not applicable given the lack of earnings, whereas the forward P/E ratio is listed at 5.83, implying that market expectations for future earnings are based on projected profitability rather than historical performance. The price-to-book ratio is 175.00, which indicates a substantial market premium over the company's book value, a common characteristic for biotechnology firms where asset values are driven by intangible intellectual property rather than physical capital. Price-to-sales and EV/EBITDA metrics are not available due to the absence of sales revenue and EBITDA figures, meaning alternative valuation methods relying on sales multiples or enterprise value multiples cannot be calculated for this specific data set. The stock has traded between a 52-week low of $0.31 and a 52-week high of $3.33, placing the current valuation context within a wide trading range that reflects the high volatility typical of small-cap clinical development companies. The beta value is not available, which prevents a direct comparison of the stock's price volatility relative to the broader market, though the wide range between the high and low suggests significant price instability.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not applicable, as the company has not yet generated revenue to establish a growth trajectory or a history of profitable earnings. Since the company does not pay dividends, the dividend yield is not applicable and the payout ratio is 0.0%, indicating that the company reinvests all available resources and any remaining cash flow back into its research and development efforts rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of historical financial performance metrics, reflecting the early clinical stage of the business where capital allocation is strictly focused on advancing the JNS101 product through Phase II trials for Friedreich's Ataxia.